Smith & Nephew SNATS (NYSE:SNN) Upgraded to "Strong-Buy" at Wall Street Zen

Key Points

• Wall Street Zen upgraded Smith & Nephew (NYSE:SNN) from a "buy" to a "strong‑buy", but analyst coverage remains mixed — one Strong Buy and four Hold ratings, with a MarketBeat average rating of "Hold" and an average target price of $36.25.
• SNN opened at $31.69 (52‑week range $23.91–$38.79), reported quarterly revenue of $1.60 billion and EPS of $29.55, has a current ratio of 2.57 and debt/equity of 0.60, and institutional investors own about 25.64% of the stock.

Smith & Nephew SNATS (NYSE:SNN - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research report issued on Sunday.

Several other equities analysts have also commented on SNN. Canaccord Genuity Group upped their price target on shares of Smith & Nephew SNATS from $34.00 to $35.00 and gave the stock a "hold" rating in a research report on Thursday, March 5th. Royal Bank Of Canada lowered shares of Smith & Nephew SNATS from an "outperform" rating to a "sector perform" rating in a research note on Monday, December 15th. Finally, Weiss Ratings restated a "hold (c+)" rating on shares of Smith & Nephew SNATS in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $36.25.

Smith & Nephew SNATS Stock Performance

SNN opened at $31.69 on Friday. Smith & Nephew SNATS has a one year low of $23.91 and a one year high of $38.79. The company has a current ratio of 2.57, a quick ratio of 1.25 and a debt-to-equity ratio of 0.60. The business's 50-day simple moving average is $34.29 and its 200-day simple moving average is $34.42.

Smith & Nephew SNATS (NYSE:SNN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 17th. The medical equipment provider reported $29.55 EPS for the quarter. The company had revenue of $1.60 billion for the quarter. Analysts forecast that Smith & Nephew SNATS will post 1.69 EPS for the current year.

Hedge Funds Weigh In On Smith & Nephew SNATS

Large investors have recently made changes to their positions in the business. Paradigm Asset Management Co. LLC acquired a new stake in Smith & Nephew SNATS during the third quarter valued at approximately $1,502,000. Todd Asset Management LLC acquired a new position in Smith & Nephew SNATS in the third quarter worth approximately $26,319,000. Citigroup Inc. grew its position in Smith & Nephew SNATS by 44.8% in the third quarter. Citigroup Inc. now owns 486,661 shares of the medical equipment provider's stock worth $17,661,000 after buying an additional 150,517 shares during the last quarter. Factory Mutual Insurance Co. bought a new position in shares of Smith & Nephew SNATS in the third quarter valued at $1,007,000. Finally, Teachers Retirement System of The State of Kentucky bought a new position in shares of Smith & Nephew SNATS in the third quarter valued at $16,501,000. Institutional investors own 25.64% of the company's stock.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.